Clinical trial
Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier Disruption for the Treatment of High Grade Glioma in Patients Undergoing Standard Chemotherapy
NCT03551249 is registered in ClinicalTrials.gov with InSightec as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier Disruption for the Treatment of High Grade Glioma in Patients Undergoing Standard Chemotherapy
- Lead sponsor
- InSightec
- Phase
- Not applicable
- Overall status
- Completed
- Start date
- March 26, 2019
- Completion date
- December 31, 2023
- Enrollment
- 20 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.